AVOIDING ACYCLOVIR NEUROTOXICITY IN PATIENTS WITH CHRONIC-RENAL-FAILURE UNDERGOING HEMODIALYSIS

Acute neurotoxicity following the administration of the recommended or al dose of acyclovir (800 mg twice daily) to dialysis-dependent patien ts is increasingly recognised. This suggests that the recommended dose is too high. Little is known of the pharmacokinetics of oral acyclovi r in dialysis patients, We studied 7 patients with oliguric end stage renal failure receiving haemodialysis. Following haemodialysis, each p atient received a single 800-mg tablet of acyclovir. Plasma acyclovir levels were monitored over the next 48 h as well as before and after t he next routine dialysis. Peak plasma levels were achieved at 3 h (12. 54 +/- 1.76 mu M, range 8.5-17.5 mu M) with the half-life calculated t o be 20.2 +/- 4.6 h. Mean plasma levels of 6.29 +/- 0.94 mu M were wit hin the quoted range to inhibit herpes tester virus (4-8 mu M) at 18 h . Haemodialysis (4-5 h) eliminated 51 +/- 11.5% of the acyclovir which remained at 48 h. Computer modelling of various dose modifications su ggests that a loading dose of 400 mg acid a maintenance dose of 200 mg twice daily is sufficient to maintain a mean plasma acyclovir level o f 6.4 +/- 0.8 mu M A further loading dose (400 mg) after dialysis woul d raise the residual acyclovir concentration by 6.1 +/- 1.0 mu M. Such a dose modification should prevent neurotoxicity, whilst the rapid el imination of acyclovir by a single haemodialysis treatment provides bo th a diagnostic and therapeutic tool when toxicity is suspected.